A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Public ClinicalTrials.gov record NCT06045689. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when administered at the maximum approved dose in low-risk Myelodysplastic Syndrome participants who require red blood cell transfusions.
Study identification
- NCT ID
- NCT06045689
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 106 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2023
- Primary completion
- Sep 30, 2025
- Completion
- Sep 28, 2027
- Last update posted
- Jun 14, 2026
2023 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0051 | Los Alamitos | California | 90720-3309 | — |
| Local Institution - 0033 | New Haven | Connecticut | 06510 | — |
| Local Institution - 0055 | St. Petersburg | Florida | 33705 | — |
| Local Institution - 0056 | Wellington | Florida | 33414 | — |
| Local Institution - 0020 | Kansas City | Kansas | 66160-8500 | — |
| Local Institution - 0025 | Paducah | Kentucky | 42003-7915 | — |
| Local Institution - 0011 | Detroit | Michigan | 48202 | — |
| Local Institution - 0059 | St Louis | Missouri | 63110 | — |
| Local Institution - 0058 | Morristown | New Jersey | 07960-6136 | — |
| Local Institution - 0032 | New York | New York | 10029 | — |
| Local Institution - 0054 | Eugene | Oregon | 97401-6043 | — |
| Local Institution - 0036 | Pittsburgh | Pennsylvania | 15224 | — |
| Local Institution - 0043 | Amarillo | Texas | 79106-1781 | — |
| Local Institution - 0022 | Huntsville | Texas | 77340-4101 | — |
| Local Institution - 0031 | Wheeling | West Virginia | 26003 | — |
| Local Institution - 0003 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
Recently updated Myelodysplastic Syndromes trials
Other public records listing Myelodysplastic Syndromes. Sorted by last update posted; newest first. Not a recommendation.
- NCT05457010: Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS Active, not recruiting
- NCT06529731: Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation Recruiting
- NCT05483010: Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS) Recruiting
- NCT02598661: Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Active, not recruiting
- NCT06566742: A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. Recruiting
- NCT06551584: Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06045689, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2026 · Synced Jul 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06045689 live on ClinicalTrials.gov.